Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.69 |
| ▸ | PTGIR | P43119 | 1/20 | 0.69 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640287 | 0.86 | PTGDR2 (0.73) | PTGDR2PTGIRPTGDRPDE10AKDM4E | |
| SCHEMBL14658903 | 0.86 | PTGDR2 (0.76) | PTGDR2PTGIRPTGDRPDE10AKDM4E | |
| Timapiprant SCHEMBL29379400 | 0.82 | PTGDR2 (1.00) | PTGDR2PTGIRPTGDR | |
| Timapiprant SCHEMBL29648518 | 0.82 | PTGDR2 (1.00) | PTGDR2PTGIRPTGDR | |
| Timapiprant SCHEMBL1782956 | 0.82 | PTGDR2 (1.00) | PTGDR2PTGIRPTGDR | |
| SCHEMBL27699143 | 0.81 | PTGDR2 (0.68) | PTGDR2PTGIRPTGDRPDE10A | |
| SCHEMBL16558834 | 0.80 | PTGDR2 (0.82) | PTGDR2PTGIRPTGDR | |
| SCHEMBL27978015 | 0.80 | PTGDR2 (0.72) | PTGDR2PTGIRPTGDR | |
| SCHEMBL12527142 | 0.79 | PTGDR2 (0.66) | PTGDR2PTGIRPTGDRPDE10AKDM4E | |
| SCHEMBL22167497 | 0.79 | PTGDR2 (0.80) | PTGDR2PTGIRPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102658-B2 | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-y1)-acetic acid esters | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-8980918-B2 | Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-03-17 | — | — | US | disclosed |
| US-20140350264-A1 | Process for the Preparation of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-Acetic Acid Esters | OXAGEN LIMITED (GB) | 2014-11-27 | — | — | US | disclosed |
| US-20140255340-A1 | Amorphous (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-Acetic Acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-8703956-B2 | Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2014-04-22 | — | — | US | disclosed |
| US-20120282223-A1 | Amorphous (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-Acetic Acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140255340-A1 | Amorphous (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-Acetic Acid | HRH2, PTGDR2, PTGDR | PTGDR2 2/4885PTGIR 41/4885PTGDR 3/4885 |
| US-20120282223-A1 | Amorphous (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-Acetic Acid | HRH2, PTGDR2, PTGDR | PTGDR2 2/4885PTGIR 41/4885PTGDR 3/4885 |
| US-20140350264-A1 | Process for the Preparation of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-Acetic Acid Esters | ADH1C, ALDH7A1, AKR1C1 | PTGDR2 2823/4885PTGIR 3392/4885PTGDR 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.